YONGIN, South Korea, April 6, 2026
GC Biopharma has announced a major advancement in intravenous immunoglobulin (IVIG) safety monitoring with the development of a proprietary analytical technology for detecting prothrombotic impurities, addressing a critical challenge in plasma-derived biologics manufacturing. The company’s newly validated enzyme-linked immunosorbent assay (ELISA) enables precise measurement of Factor XI (FXI)—a key impurity associated with thromboembolic risks—marking a significant step forward in biopharmaceutical quality control and patient safety. The findings have been published in the Journal of Microbiology and Biotechnology, reinforcing the scientific credibility of this innovation.
Advanced Analytical Technology Improves Impurity Detection
The newly developed ELISA platform incorporates a novel IgG Blocker technology, designed to eliminate heterophilic antibody interference, a major limitation in traditional IVIG testing methods. High concentrations of immunoglobulin G (IgG) in IVIG products have historically led to false-positive results or masked detection of trace impurities, complicating quality assurance processes.
By selectively suppressing non-specific protein interactions, the new assay enables accurate, interference-free quantification of FXI levels, ensuring enhanced analytical precision even in complex biologic matrices. This breakthrough significantly improves the reliability of impurity detection, a critical requirement for maintaining clinical-grade purity in plasma-derived therapies.
Strengthening GMP Compliance and Regulatory Alignment
Advertisement
The assay has been fully validated in accordance with ICH Q2(R2) guidelines, demonstrating its robustness, accuracy, and reproducibility in line with global regulatory expectations for analytical method validation. Regulatory agencies, including the U.S. Food and Drug Administration (FDA), have increasingly emphasized the need for rigorous monitoring of procoagulant impurities such as Factor XI due to their association with serious adverse events, including thrombosis.
GC Biopharma’s innovation directly supports Good Manufacturing Practice (GMP) requirements, enabling manufacturers to implement risk-based quality control strategies and ensure batch consistency. This advancement aligns with the broader industry trend toward precision analytics and enhanced pharmacovigilance in biologics production.
Enhancing Patient Safety in Plasma-Derived Therapies
IVIG therapies are widely used in the treatment of immune deficiencies, autoimmune disorders, and inflammatory diseases, making their safety profile a top priority for both clinicians and regulators. Thromboembolic complications linked to residual coagulation factors have been a longstanding concern, necessitating continuous improvements in manufacturing and testing technologies.
The introduction of this high-sensitivity FXI detection method enables earlier identification and mitigation of potential risks, ultimately contributing to safer therapeutic outcomes for patients worldwide. By integrating advanced analytical science into its production pipeline, GC Biopharma reinforces its commitment to delivering high-quality, safe, and effective biologic medicines.
Driving Innovation in Biopharmaceutical Quality Control
This development highlights GC Biopharma’s broader strategy to leverage cutting-edge R&D capabilities in protein engineering, analytical science, and biologics manufacturing. As the global demand for plasma-derived therapies continues to grow, the need for robust impurity detection and quality assurance technologies becomes increasingly critical.
The company’s precision-driven approach sets a new benchmark for analytical excellence in the biopharmaceutical industry, supporting both regulatory compliance and innovation in therapeutic development. This advancement also underscores the evolving role of advanced diagnostics and analytical platforms in ensuring the safety and efficacy of complex biologic products.
Source: GC Biopharma press release
